Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Recurrent Multiple Myeloma”

714 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 714 results

Testing effectiveness (Phase 2)WithdrawnNCT05170789
What this trial is testing

Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma

Who this might be right for
Relapsed Multiple MyelomaRefractory Multiple Myeloma
Tulane University School of Medicine
Early research (Phase 1)Not Yet RecruitingNCT07113496
What this trial is testing

RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies

Who this might be right for
Relapsed or Refractory B-cell Hematologic MalignanciesB-cell Acute Lymphoblastic Leukemia (B-ALL)Multiple Myeloma (MM)+3 more
The First Affiliated Hospital with Nanjing Medical University 27
Early research (Phase 1)Looking for participantsNCT05652335
What this trial is testing

JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

Who this might be right for
Relapsed or Refractory Multiple MyelomaPreviously Treated Amyloid Light-chain (AL) Amyloidosis
Janssen Research & Development, LLC 180
Not applicableUnknownNCT00295997
What this trial is testing

Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia

Who this might be right for
Chronic Myeloproliferative DisordersKidney CancerLeukemia+4 more
University of California, San Francisco 35
Testing effectiveness (Phase 2)Study completedNCT02206425
What this trial is testing

Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

Who this might be right for
Multiple Myeloma
Oncotherapeutics 45
Early research (Phase 1)Study completedNCT00005946
What this trial is testing

Chemotherapy Plus Donor White Blood Cell Infusion in Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell Transplantation

Who this might be right for
LeukemiaLymphomaMultiple Myeloma and Plasma Cell Neoplasm+1 more
University of Maryland, Baltimore
Testing effectiveness (Phase 2)Looking for participantsNCT05594797
What this trial is testing

Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM

Who this might be right for
Multiple Myeloma
Hrain Biotechnology Co., Ltd. 100
Testing effectiveness (Phase 2)Looking for participantsNCT07410494
What this trial is testing

Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors

Who this might be right for
CancerBreast CancerNon-Small Cell Lung Cancer (NSCLC)+10 more
Essen Biotech 85
Early research (Phase 1)Study completedNCT00891137
What this trial is testing

Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy

Who this might be right for
LeukemiaLymphomaMultiple Myeloma+2 more
Cellerant Therapeutics 30
Very early researchLooking for participantsNCT06718270
What this trial is testing

CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia

Who this might be right for
Relapsed/Refractory Multiple MyelomaRelapsed/Refractory Plasma Cell Leukemia
Shanghai Changzheng Hospital 24
Early research (Phase 1)Study completedNCT00569283
What this trial is testing

Donor Natural Killer Cell Infusion in Preventing Relapse or Graft Failure in Patients Who Have Undergone Donor Bone Marrow Transplant

Who this might be right for
Cancer
Asan Medical Center 18
Early research (Phase 1)Study completedNCT01359657
What this trial is testing

Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Bristol-Myers Squibb 46
Early research (Phase 1)UnknownNCT05052970
What this trial is testing

Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM

Who this might be right for
Relapsed or Refractory Multiple Myeloma
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. 60
Testing effectiveness (Phase 2)Ended earlyNCT04205240
What this trial is testing

Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma

Who this might be right for
Recurrent Plasma Cell Myeloma
Srinivas Devarakonda 1
Testing effectiveness (Phase 2)Ended earlyNCT03303950
What this trial is testing

Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis

Who this might be right for
AnemiaASXL1 Gene MutationEZH2 Gene Mutation+7 more
University of Utah 6
Early research (Phase 1)Ended earlyNCT04895410
What this trial is testing

Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma

Who this might be right for
Multiple Myeloma
AbbVie 8
Testing effectiveness (Phase 2)WithdrawnNCT03328936
What this trial is testing

Study of Personalized Melphalan Dosing in the Setting of Autologous Transplant

Who this might be right for
Hematopoietic Cell Transplantation RecipientRecurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Ohio State University Comprehensive Cancer Center
Testing effectiveness (Phase 2)WithdrawnNCT03841565
What this trial is testing

Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Who this might be right for
Recurrent Plasma Cell Myeloma
Academic and Community Cancer Research United
Testing effectiveness (Phase 2)Study completedNCT01085214
What this trial is testing

AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma

Who this might be right for
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
National Cancer Institute (NCI) 37
Testing effectiveness (Phase 2)Ended earlyNCT01116128
What this trial is testing

Dasatinib in Combination With Melphalan and Prednisone to Treat Relapsed and Refractory Multiple Myeloma Patients

Who this might be right for
Myeloma
Fondazione EMN Italy Onlus 8
Load More Results